Rare Congenital Fibrinogen Deficiencies

References

1.         Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3:1894-904.

2.         Acharya SS, Dimichele DM. Rare inherited disorders of fibrinogen. Haemophilia. 2008;14:1151-8.

3.         de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost. 2009;35:356-66.

4.         Asselta R, Duga S, Tenchini ML. The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost. 2006;4:2115-29.

5.         Mosesson MW. Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost. 2003;89:9-12.

6.         Kant JA, Fornace AJ, Jr., Saxe D, Simon MI, McBride OW, Crabtree GR. Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci U S A. 1985;82:2344-8.

7.         Rabe F, Salomon E. [Über Faserstoffmangel im Blut bei einem Fall von Haemophile]. Deut Arch Klin Med. 1920;132:240-4.

8.         Werder E. [Congenital Afibrinogenemia]. Helv Paediatr Acta. 1963;18:208-29.

9.         Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost. 2006;4:1634-7.

10.       Krammer B, Anders O, Nagel HR, Burstein C, Steiner M. Screening of dysfibrinogenaemia using the fibrinogen function versus antigen concentration ratio. Thromb Res. 1994;76:577-9.

11.       Peyvandi F, Duga S, Akhavan S, Mannucci PM. Rare coagulation deficiencies. Haemophilia. 2002;8:308-21.

12.       Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol. 1999;107:204-6.

13.       World Federation of Hemophilia Report on the Annual Global Survey 2009. Montreal, Quebec, Canada. 2011. Access date: August 14, 2013. Available from: http://www1.wfh.org/publications/files/pdf-1428.pdf

14.       Peyvandi F, Palla R, Menegatti M, Siboni SM, Halimeh S, Faeser B, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost. 2012;10:615-21.

15.       Mathonnet F, Peltier JY, Roda L, de Raucourt E, D’Hailly F, Tetegan M, et al. Three new cases of dysfibrinogenemia: Poissy III, Saint-Germain I and Tahiti. Thromb Res. 2001;103:201-7.

16.       Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood. 2004;104:1243-52.

17.       Acharya SS, Coughlin A, Dimichele DM, North American Rare Bleeding Disorder Study G. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost. 2004;2:248-56.

18.       Neerman-Arbez M, de Moerloose P, Bridel C, Honsberger A, Schonborner A, Rossier C, et al. Mutations in the fibrinogen aalpha gene account for the majority of cases of congenital afibrinogenemia. Blood. 2000;96:149-52.

19.       Vu D, de Moerloose P, Batorova A, Lazur J, Palumbo L, Neerman-Arbez M. Hypofibrinogenaemia caused by a novel FGG missense mutation (W253C) in the gamma chain globular domain impairing fibrinogen secretion. J Med Genet. 2005;42:e57.

20.       Casini A, Lukowski S, Quintard VL, Crutu A, Zak M, Regazzoni S, et al. FGB mutations leading to congenital quantitative fibrinogen deficiencies: an update and report of four novel mutations. Thromb Res. 2014;133:868-74.

21.       Hanss M, Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci. 2001;936:89-90.

22.       Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost. 1995;73:151-61.

23.       Bornikova L, Peyvandi F, Allen G, Bernstein J, Manco-Johnson MJ. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost. 2011;9:1687-704.

24.       Neerman-Arbez M. The molecular basis of inherited afibrinogenaemia. Thromb Haemost. 2001;86:154-63.

25.       al-Mondhiry H, Ehmann WC. Congenital afibrinogenemia. Am J Hematol. 1994;46:343-7.

26.       Casini A, Sokollik C, Lukowski SW, Lurz E, Rieubland C, de Moerloose P, et al. Hypofibrinogenemia and liver disease: a new case of Aguadilla fibrinogen and review of the literature. Haemophilia. 2015;21:820-7.

27.       Kobayashi T, Asahina T, Maehara K, Itoh M, Kanayama N, Terao T. Congenital afibrinogenemia with successful delivery. Gynecol Obstet Invest. 1996;42:66-9.

28.       Rubbia-Brandt L, Neerman-Arbez M, Rougemont AL, Male PJ, Spahr L. Fibrinogen gamma375 arg–>trp mutation (fibrinogen aguadilla) causes hereditary hypofibrinogenemia, hepatic endoplasmic reticulum storage disease and cirrhosis. Am J Surg Pathol. 2006;30:906-11.

29.       Girolami A, Ruzzon E, Tezza F, Scandellari R, Vettore S, Girolami B. Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review. Haemophilia. 2006;12:345-51.

30.       De Mattia D, Regina G, Giordano P, Del Vecchio GC, Altomare M, Schettini F. Association of congenital afibrinogenemia and K-dependent protein C deficiency–a case report. Angiology. 1993;44:745-9.

31.       Dupuy E, Soria C, Molho P, Zini JM, Rosenstingl S, Laurian C, et al. Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin. Thromb Res. 2001;102:211-9.

32.       Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106:385-92.

33.       Palascak JE, Martinez J. Dysfibrinogenemia associated with liver disease. J Clin Invest. 1977;60:89-95.

34.       Francis JL, Armstrong DJ. Fibrinogen-bound sialic acid levels in the dysfibrinogenaemia of liver disease. Haemostasis. 1982;11:215-22.

35.       Dawson NA, Barr CF, Alving BM. Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma. Am J Med. 1985;78:682-6.

36.       Gralnick HR, Henderson E. Hypofibrinogenemia and coagulation factor deficiencies with L-asparaginase treatment. Cancer. 1971;27:1313-20.

37.       Hauser E, Seidl R, Freilinger M, Male C, Herkner K. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev. 1996;18:105-9.

38.       Francis JL, Armstrong DJ. Sialic acid and enzymatic desialation of cord blood fibrinogen. Haemostasis. 1982;11:223-8.

39.       Martinez J, Keane PM, Gilman PB, Palascak JE. The abnormal carbohydrate composition of the dysfibrinogenemia associated with liver disease. Ann N Y Acad Sci. 1983;408:388-96.

40.       Van Cott EM, Smith EY, Galanakis DK. Elevated fibrinogen in an acute phase reaction prolongs the reptilase time but typically not the thrombin time. Am J Clin Pathol. 2002;118:263-8.

41.       Manco-Johnson MJ, Dimichele D, Castaman G, Fremann S, Knaub S, Kalina U, et al. Pharmacokinetics and safety of fibrinogen concentrate. J Thromb Haemost. 2009;7:2064-9.

42.       Rossi E, Mondonico P, Lombardi A, Preda L. Method for the determination of functional (clottable) fibrinogen by the new family of ACL coagulometers. Thromb Res. 1988;52:453-68.

43.       Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965;2:235-54.

44.       Hayes T. Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med. 2002;126:1387-90.

45.       Lefkowitz JB, DeBoom T, Weller A, Clarke S, Lavrinets D. Fibrinogen Longmont: a dysfibrinogenemia that causes prolonged clot-based test results only when using an optical detection method. Am J Hematol. 2000;63:149-55.

46.       XXV Congress of the International Society on Thrombosis and Haemostasis. Fibrinogen deficiency:  preliminary results of the PRO-RBDD project. Toronto, Canada.

47.       Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4:1073-81.

48.       Casini A, Neerman-Arbez M, Ariens RA, de Moerloose P. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost. 2015;13:909-19.

49.       Shapiro SE, Phillips E, Manning RA, Morse CV, Murden SL, Laffan MA, et al. Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia. Br J Haematol. 2013;160:220-7.

50.       Santacroce R, Cappucci F, Pisanelli D, Perricone F, Papa ML, Santoro R, et al. Inherited abnormalities of fibrinogen: 10-year clinical experience of an Italian group. Blood Coagul Fibrinolysis. 2006;17:235-40.

51.       Miesbach W, Scharrer I, Henschen A, Neerman-Arbez M, Spitzer S, Galanakis D. Inherited dysfibrinogenemia: clinical phenotypes associated with five different fibrinogen structure defects. Blood Coagul Fibrinolysis. 2010;21:35-40.

52.       Casini A, Blondon M, Lebreton A, Koegel J, Tintillier V, de Maistre E, et al. Natural history of patients with congenital dysfibrinogenemia. Blood. 2015;125:553-61.

53.       Zhou J, Ding Q, Chen Y, Ouyang Q, Jiang L, Dai J, et al. Clinical features and molecular basis of 102 Chinese patients with congenital dysfibrinogenemia. Blood Cells Mol Dis. 2015;55:308-15.

54.       Asselta R, Robusto M, Braidotti P, Peyvandi F, Nastasio S, D’Antiga L, et al. Hepatic fibrinogen storage disease: identification of two novel mutations (p.Asp316Asn, fibrinogen Pisa and p.Gly366Ser, fibrinogen Beograd) impacting on the fibrinogen gamma-module. J Thromb Haemost. 2015;13:1459-67.

55.       Neerman-Arbez M. To aggregate or not to aggregate. J Thromb Haemost. 2007;5:1997-8.

56.       Haidinger M, Werzowa J, Kain R, Antlanger M, Hecking M, Pfaffenberger S, et al. Hereditary amyloidosis caused by R554L fibrinogen Aalpha-chain mutation in a Spanish family and review of the literature. Amyloid. 2013;20:72-9.

57.       Tavares I, Lobato L, Moreira L, Santos J, Lacerda P, Pinheiro J, et al. Long-term follow-up of patients with hereditary fibrinogen A alpha-chain amyloidosis. Amyloid. 2011;18 Suppl 1:221-2.

58.       Kalina U, Stohr HA, Bickhard H, Knaub S, Siboni SM, Mannucci PM, et al. Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. Blood Coagul Fibrinolysis. 2008;19:777-83.

59.       Trelinski J, Pachniewska K, Matczak J, Robak M, Chojnowski K. Assessment of Selected ROTEM Parameters, Kinetics of Fibrinogen Polymerization and Plasmin Amidolytic Activity in Patients with Congenital Fibrinogen Defects. Adv Clin Exp Med. 2016;25:1255-63.

60.       Wohner N, Sotonyi P, Machovich R, Szabo L, Tenekedjiev K, Silva MM, et al. Lytic resistance of fibrin containing red blood cells. Arterioscler Thromb Vasc Biol. 2011;31:2306-13.

61.       Undas A, Zawilska K, Ciesla-Dul M, Lehmann-Kopydlowska A, Skubiszak A, Ciepluch K, et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood. 2009;114:4272-8.

62.       Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev. 2007;21:131-42.

63.       Szczepaniak P, Zabczyk M, Undas A. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study. PLoS One. 2015;10:e0125069.

64.       Bridge KI, Philippou H, Ariens R. Clot properties and cardiovascular disease. Thromb Haemost. 2014;112:901-8.

65.       Ariens RA. Fibrin(ogen) and thrombotic disease. J Thromb Haemost. 2013;11 Suppl 1:294-305.

66.       Undas A, Pastuszczak M, Iwaniec T, Kapelak K, Neerman-Arbez M. Functional characterisation of plasma fibrin clots in Polish carriers of fibrinogen gammaArg275His mutation (fibrinogen Zabrze). Thromb Haemost. 2010;104:415-7.

67.       Kotlin R, Pastva O, Stikarova J, Hlavackova A, Suttnar J, Chrastinova L, et al. Two novel mutations in the fibrinogen gamma nodule. Thromb Res. 2014;134:901-8.

68.       Pietrys D, Balwierz W, Iwaniec T, Vorjohann S, Neerman-Arbez M, Undas A. Two different fibrinogen gene mutations associated with bleeding in the same family (A alphaGly13Glu and gammaGly16Ser) and their impact on fibrin clot properties: fibrinogen Krakow II and Krakow III. Thromb Haemost. 2011;106:558-60.

69.       Sugo T, Endo H, Matsuda M, Ohmori T, Madoiwa S, Mimuro J, et al. A classification of the fibrin network structures formed from the hereditary dysfibrinogens. J Thromb Haemost. 2006;4:1738-46.

70.       Marsh JJ, Chiles PG, Liang NC, Morris TA. Chronic thromboembolic pulmonary hypertension-associated dysfibrinogenemias exhibit disorganized fibrin structure. Thromb Res. 2013;132:729-34.

71.       Casini A, Duval C, Pan X, Tintillier V, Biron-Andreani C, Ariens RA. Fibrin clot structure in patients with congenital dysfibrinogenaemia. Thromb Res. 2016;137:189-95.

72.       Kreuz W, Meili E, Peter-Salonen K, Haertel S, Devay J, Krzensk U, et al. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apher Sci. 2005;32:247-53.

73.       Santagostino E, Mancuso ME, Morfini M, Schiavoni M, Tagliaferri A, Barillari G, et al. Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. Haematologica. 2006;91:634-9.

74.       Peyvandi F. Results of an international, multicentre pharmacokinetic trial in congenital fibrinogen deficiency. Thromb Res. 2009;124 Suppl 2:S9-11.

75.       Ratnoff O. Acquired disorders of hemostasis. In: Colman RW, Hirsch J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis:  Basic Principles and Clinical Practice. 3rd ed. Philadelphia: J. B. Lippincott Company, 1994: 1107-8.

76.       Rizk DE, Kumar RM. Congenital afibrinogenemia: treatment of excessive menstrual bleeding with continuous oral contraceptive. Am J Hematol. 1996;52:237-8.

77.       De Vries A, Rosenberg T, Kochwa S, Boss JH. Precipitating antifibrinogen antibody appearing after fibrinogen infusions in a patient with congenital afibrinogenemia. Am J Med. 1961;30:486-94.

78.       Ra’anani P, Levi Y, Varon D, Gitel S, Martinowitz U. [Congenital afibrinogenemia with bleeding, bone cysts and antibodies to fibrinogen]. Harefuah. 1991;121:291-3.

79.       Schuepbach RA, Meili EO, Schneider E, Peter U, Bachli EB. Lepirudin therapy for thrombotic complications in congenital afibrinogenaemia. Thromb Haemost. 2004;91:1044-6.

80.       Casini A, de Moerloose P, Congenital Fibrinogen Disorders G. Management of congenital quantitative fibrinogen disorders: a Delphi consensus. Haemophilia. 2016;22:898-905.

81.       Huq FY, Kadir RA. Management of pregnancy, labour and delivery in women with inherited bleeding disorders. Haemophilia. 2011;17 Suppl 1:20-30.

82.       Roque H, Stephenson C, Lee MJ, Funai EF, Popiolek D, Kim E, et al. Pregnancy-related thrombosis in a woman with congenital afibrinogenemia: a report of two successful pregnancies. Am J Hematol. 2004;76:267-70.

83.       Trehan AK, Fergusson IL. Congenital afibrinogenaemia and successful pregnancy outcome. Case report. Br J Obstet Gynaecol. 1991;98:722-4.

84.       Kreuz W, Meili E, Peter-Salonen K, Dobrkovska A, Devay J, Haertel S, et al. Pharmacokinetic properties of a pasteurised fibrinogen concentrate. Transfus Apher Sci. 2005;32:239-46.

 

Next